The UK and US have hammered out a major bilateral deal that will preserve zero levies on British drug shipments going into the American market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to raise expenditure on drugs through the public health system. This pledge guarantees that duties on these key products will be held at zero for a duration of 36 months.
This deal is in response to previous statements to dramatically increase import taxes on patented pharmaceutical products, with potential rates discussed as high as 100%.
"This deal between the UK reinforces the international landscape for innovative medicines and introduces long-overdue balance to U.S.–U.K. drug exports," a statement declared.
Commercial Importance
Drugs constitute one of the the United Kingdom's most significant goods shipped to the US, which is easily the biggest destination for leading British pharmaceutical firms.
Trade data show that in the year prior to the third quarter, the UK shipped drugs totaling £11.1bn to the US. This value made up a significant portion of total UK exports in that span.
"This guarantee safeguards employment, boosts capital expenditure and paves the way for the UK to become a worldwide center for biotech and pharma," a government official remarked.
Detailed NHS Changes
The pact includes several specific commitments from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double total health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount manufacturers must refund to the NHS to prevent overspending will be capped at 15%. In the past, rebates topped twenty percent.
Industry Background
The pact takes place against a ongoing row between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
These tensions were intensified by arguments that US customers were paying several times more for the equivalent treatments than consumers in the UK and Europe.
Recently, several major drug company projects in the UK have been delayed or scrapped, while substantial expansions have been directed toward American operations.
One official publicly accepted that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a share of its overall budget over the last ten years.
